BiotechTube

Acalabrutinib Treatment A + Acalabrutinib Treatment B + Acalabrutinib Treatment C + Acalabrutinib Treatment D

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mantle Cell Lymphoma

Conditions

Mantle Cell Lymphoma, COVID-19

Trial Timeline

Oct 12, 2020 → Dec 11, 2020

NCT ID
NCT04564040

About Acalabrutinib Treatment A + Acalabrutinib Treatment B + Acalabrutinib Treatment C + Acalabrutinib Treatment D

Acalabrutinib Treatment A + Acalabrutinib Treatment B + Acalabrutinib Treatment C + Acalabrutinib Treatment D is a phase 1 stage product being developed by AstraZeneca for Mantle Cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04564040. Target conditions include Mantle Cell Lymphoma, COVID-19.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04564040Phase 1Completed

Competing Products

20 competing products in Mantle Cell Lymphoma

See all competitors
ProductCompanyStageHype Score
Pirtobrutinib + Brexucabtagene AutoleucelEli LillyPhase 2
52
Obinutuzumab + Glofitamab + PirtobrutinibEli LillyPhase 2
52
enzastaurinEli LillyPhase 2
52
AbemaciclibEli LillyPhase 2
52
Pirtobrutinib + Ibrutinib + Acalabrutinib + ZanubrutinibEli LillyPhase 3
77
Pirtobrutinib + Rituximab + VenetoclaxEli LillyPhase 2
52
Pirtobrutinib and rituximabEli LillyPhase 2
52
gemcitabine + mitoxantrone + rituximabEli LillyPhase 2
52
Rituximab 375 mg/m^2 + Cyclophosphamide 750 mg/m^2 + Doxorubicin 50 mg/m^2 + VELCADE 1.3 mg/m^2 + Prednisone 100 mg/m^2 + Vincristine 1.4 mg/m^2Johnson & JohnsonPhase 3
77
VenetoclaxAbbViePhase 2
52
Ibrutinib + VenetoclaxAbbViePhase 2
52
ABT-199 and Ibrutinib CombinationAbbViePhase 1
33
Venetoclax Oral Tablet [Venclexta]AbbViePhase 2
52
Acalabrutinib capsuleAstraZenecaApproved
85
Acalabrutinib in combination with BR + Acalabrutinib in combination with VRAstraZenecaPhase 1
33
Acalabrutinib + Venetoclax + ObinutuzumabAstraZenecaPhase 1/2
41
Acalabrutinib + R-CHOP standard of care + Acalabrutinib combination with Rituximab + Acalabrutinib monotherapyAstraZenecaPhase 2
52
Acalabrutinib + Venetoclax + RituximabAstraZenecaPhase 2
52
Acalabrutinib + RituximabAstraZenecaPhase 2
52
Acalabrutinib + Lenalidomide + Rituximab + ObinutuzumabAstraZenecaPhase 2
52

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85